EnChannel Medical将收购Acutus Medical的AcQMap™电生理资产-动脉网

EnChannel Medical to Acquire Acutus Medical AcQMap™ Electrophysiology Assets

CISION 等信源发布 2025-07-01 20:00



可切换为仅中文







IRVINE, Calif.

加利福尼亚州欧文市

，

July 1, 2025

2025年7月1日

/PRNewswire/ --

/美通社/ --

EnChannel Medical Ltd.

恩通道医疗有限公司

, a global leader in cardiac electrophysiology innovation, today announced it has signed a definitive agreement to acquire the AcQMap™ High Resolution Imaging and Mapping platform assets from Acutus Medical Inc. The acquisition includes substantive intellectual property, quality and regulatory documentation, clinical data, a limited number of AcQMap™ systems, and associated catheter devices for research and development purposes..

，心脏电生理创新领域的全球领导者，今天宣布已签署了一项最终协议，将从Acutus Medical Inc.收购AcQMap™高分辨率成像与标测平台资产。此次收购包括大量的知识产权、质量与监管文件、临床数据、少量AcQMap™系统以及用于研究和开发的相关导管设备。

Electrophysiological source pyramid

电生理源金字塔

This acquisition significantly strengthens EnChannel's intellectual property portfolio by integrating key innovations in second- and third-generation non-contact mapping (NCM) technologies. These technologies form the foundation for full-chamber atrial fibrillation (AF) mapping – a critical capability for understanding AF mechanisms and delivering effective, personalized treatment..

此次收购通过整合第二代和第三代非接触式标测（NCM）技术的关键创新，大幅增强了EnChannel的知识产权组合。这些技术为全心房颤动（AF）标测奠定了基础——这是理解AF机制并提供有效、个性化治疗的关键能力。

'This strategic acquisition accelerates our mission to visualize and treat AF with unprecedented efficiency and precision,' said

“这次战略性收购加速了我们以空前的效率和精确度可视化并治疗房颤的使命，”

Jun Feng

冯俊

, CEO of EnChannel Medical. 'By building on prior advancements and leveraging our proprietary technologies, we are shaping the future of persistent AF diagnosis and treatment.'

EnChannel Medical首席执行官表示：“通过依托先前的进展并利用我们的专有技术，我们正在塑造持续性房颤诊断和治疗的未来。”

Contact and Non-Contact Mapping in Perspective

接触与非接触映射的视角

Conventional contact mapping systems sequentially collect electrical signals by making physical contact with many small regions of cardiac tissue, generating regional maps of electrical activity over numerous beats that are gradually assembled into a composite view across the chamber surface. While effective for regular rhythms, it is time-consuming, and it cannot capture the full dynamics of irregular activation patterns, such as in AF, often averaging out critical details and reducing mapping accuracy and specificity..

传统的接触式标测系统通过与许多小区域的心脏组织进行物理接触，依次收集电信号，生成多个心跳周期的局部电活动图，并逐步将其整合为整个心腔表面的综合视图。虽然该方法对规则心律有效，但耗时较长，且无法捕捉不规则激活模式（如房颤）的完整动态，常常会平均掉关键细节，降低标测的准确性和特异性。

In contrast, non-contact mapping (NCM) reconstructs full-chamber electrical activity from cardiac signals sensed by numerous electrodes distributed within the atrial chamber cavity. NCM delivers a comprehensive, single-beat depiction of activation over the entire atrial chamber at every instance of time.

相比之下，非接触映射（NCM）通过分布在心房腔内的众多电极感知的心脏信号重建全腔室的电活动。NCM 提供了整个心房在每个时间点上单次心跳的全面激活图。

This approach significantly improves mapping efficiency and preserves the dynamic patterns of both regular and complex, irregular rhythms, including AF..

这种方法显著提高了映射效率，并保留了规则和复杂、不规则节律（包括房颤）的动态模式。

Acutus' AcQMap™ technology is a second-generation NCM platform that advanced beyond the first-generation voltage-to-voltage mapping (pioneered by Endocardial Solutions – now part of Abbott), and delivered improved spatial resolution and accuracy, using voltage-to-charge-density mapping.

Acutus的AcQMap™技术是第二代NCM平台，它超越了第一代电压到电压映射（由心内膜解决方案公司首创，现为Abbott的一部分），并通过电压到电荷密度映射提供了更高的空间分辨率和准确性。

Advancing the Frontier of Non-Contact Mapping

推进非接触映射的前沿

EnChannel's propriety Action Potential Mapping offers a third-generation breakthrough in NCM technology, with accurate reconstruction of both depolarization and repolarization dynamics. This fulfills a biophysical unmet need that remains in conventional mapping, which cannot address repolarization. Action Potential Mapping therefore approaches the real nature of cardiac conduction and enables comprehensive understanding of the mechanisms that initiate and maintain AF – laying the groundwork for precise, individualized treatment of persistent AF..

EnChannel的专有动作电位标测技术在NCM技术领域实现了第三代突破，能够准确重建去极化和复极化动态。这满足了传统标测中未能解决的生物物理需求，因为传统方法无法处理复极化。因此，动作电位标测更接近心脏传导的真实本质，并为理解和研究引发和维持房颤的机制提供了全面视角——为持续性房颤的精准个体化治疗奠定了基础。

'Many of us at EnChannel had essential roles in developing all three generations of non-contact mapping,' said

“我们EnChannel的许多人在开发所有三代非接触式地图中都发挥了关键作用，”

Graydon Beatty

格雷登·贝蒂

, CSO of EnChannel Medical. 'Each generation informed and enabled the next one; from reproduction of the cardiac signal in the first; to resolving the physical electric source of the signal in the second; and now culminating in reconstruction of the physiologic action potential in the third, revealing the actual nature of cardiac conduction dynamics.

EnChannel Medical首席科学官（CSO）。“每一代技术都为下一代提供了信息和支持；从第一代复制心脏信号，到第二代解析信号的物理电学来源，再到第三代重建生理动作电位，揭示了心脏传导动力学的真实本质。”

This acquisition unites our history of requisite methods and resources across the generations, and advances a hybrid workflow of all modes of navigation, mapping, and visualization. We are poised and resolved to establish an electrophysiology ecosystem that uncovers the mechanisms of AF, optimizes patient-specific treatment, and improves clinical outcomes in persistent AF.'.

此次收购整合了我们历代所需的方法和资源，推进了融合所有导航、绘图和可视化模式的混合工作流程。我们已准备好并决心建立一个电生理学生态系统，揭示心房颤动（AF）的机制，优化针对患者的个性化治疗，并改善持续性心房颤动的临床结果。

About EnChannel Medical

关于EnChannel Medical

Founded in 2020 by a team of seasoned electrophysiology innovators from both

成立于2020年，由一群来自双方的资深电生理学创新者创立

the United States

美国

and

和

China

中国

, EnChannel is developing a holistic platform that unifies magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and mid-voltage (<1000 V) pulsed-field ablation to deliver safe and personalized treatment for patients with atrial fibrillation. EnChannel is well positioned to expand its global innovation and advance its mission to transform AF care through data-driven, patient-specific therapy solutions..

EnChannel正在开发一个综合平台，该平台统一了磁阻抗导航、心腔内超声心动图、全腔室5D动作电位标测以及中电压（<1000 V）脉冲场消融技术，为心房颤动患者提供安全且个性化的治疗。EnChannel有能力推动其全球创新，并通过数据驱动、针对患者的治疗方案实现转变心房颤动护理的使命。

For more information, visit

欲了解更多信息，请访问

http://www.enchannel.com

and follow us on

关注我们

领英

。

EnChannel's mapping and ablation products are investigational devices and are limited by federal (or United States) law to investigational use.

EnChannel的映射和消融产品属于研究性设备，根据联邦（或美国）法律限制为研究性使用。

Media Contact

媒体联系人